When considering eligibility of post-stroke patients in studies assessing safety and efficacy of GLP-1-RA and SGLT-2 inhibitors, a clinical trial would be able to recruit roughly a quarter of our study population (207 of 884, 23.4%), if inclusion criteria would mimic those of a recent study on the efficacy of semaglutide on CVD outcome in obese adults above the age of ⩾45 years without DM II (i.e. BMI ⩾ 27 kg/m2 and normoglycemia or prediabetes at baseline) (Figure 2).12 The gene discussed is SLC5A2; the disease is stroke disorder.